
Illumina, Inc.
Illumina, Inc. is a United States-based company in the Healthcare sector with a market capitalisation of $39.7B. Its FinScore is 53/100; its highest-scoring layer is Momentum (71) and its lowest is Value (25). The shares trade at 81.9x trailing earnings and are up 95% year to date.
Share price performance
About Illumina, Inc.
www.illumina.comIllumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- HQ
- United States
- Fiscal year-end
- December
- Trading currency
- USD
- Reporting currency
- USD
- Fundamentals updated
- 81 days ago
- Market cap
- $39.7B
- Shares outstanding
- 151.0M
- P/E (TTM)
- 81.9x
- Beta (issuer)
- 1.42
- Revenue (latest FY)
- $4.3B
Revenue breakdown
- Sequencing91.8%$4.0B
- Microarray8.2%$358.0M
FinScore
As of 2026-10-19Snapshot
Ownership
As of 2026-06-30Sign up or log in to see Analysis
Analysis for Illumina, Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Financials
Financials for Illumina, Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Estimates
Estimates for Illumina, Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Peers
Peers for Illumina, Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Valuation
Valuation for Illumina, Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see News
News for Illumina, Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.